Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial
Public ClinicalTrials.gov record NCT07723235. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Health Engagement for Rural Ohio Cancer Survivors (HERO-C)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial identifies the needs and preferences of rural stage I-III postmenopausal breast and endometrial cancer survivors and evaluates the impact of an adaptive, online program, mobile (m)Health + ecological momentary assessment (EMA) intervention, on lifestyle modification and their weight loss efforts. Obesity, a condition marked by an abnormally high, unhealthy amount of body fat, is associated with lower physical and psychological well-being, higher risk of recurrence, and higher cancer-specific and all-cause mortality (number of deaths). Lifestyle factors, such as low physical activity and unhealthy diet, are the main contributors to obesity that are modifiable. Lifestyle weight loss programs focusing on modifiable factors can improve cancer-specific survival and many aspects of health, but access to these programs can be challenging in rural settings. A remote lifestyle program, adapted to individual goals and needs, may help promote healthy behaviors, improve cancer outcomes, and reduce disease burden in stage I-III postmenopausal breast and endometrial cancer survivors.
Study identification
- NCT ID
- NCT07723235
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 90 participants
Conditions and interventions
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Endometrial Carcinoma
- Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
- Aerobic Exercise Other
- Biospecimen Collection Procedure
- Dietary Intervention Other
- Discussion Other
- Goal Setting Other
- Internet-Based Intervention Other
- Medical Device Usage and Evaluation Other
- Questionnaire Administration Other
- Resistance Training Other
- Smartphone Application-based Intervention Behavioral
- Supportive Care Other
- Tailored Intervention Procedure
Other · Procedure · Behavioral
Eligibility (public fields only)
- Age range
- 40 Years to 69 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2026
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2027
- Last update posted
- Jul 22, 2026
2026 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Anatomic Stage I Breast Cancer AJCC v8 trials
Other public records listing Anatomic Stage I Breast Cancer AJCC v8. Sorted by last update posted; newest first. Not a recommendation.
- NCT07769047: Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors Not yet recruiting
- NCT07741968: A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer Not yet recruiting
- NCT07721259: A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden Not yet recruiting
- NCT07699991: A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors Not yet recruiting
- NCT07407920: Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Recruiting
- NCT07474090: Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07723235, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2026 · Synced Jul 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07723235 live on ClinicalTrials.gov.